Chromosomal imbalances of primary and metastatic lung adenocarcinomas

被引:101
作者
Goeze, A [1 ]
Schlüns, K [1 ]
Wolf, G [1 ]
Thäsler, Z [1 ]
Petersen, S [1 ]
Petersen, I [1 ]
机构
[1] Humboldt Univ, Inst Pathol, Charite Hosp, D-10098 Berlin, Germany
关键词
lung; CGH; adenocarcinoma; tumour progression;
D O I
10.1002/path.1009
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Comparative genomic hybridization (CGH) was used to screen 83 lung adenocarcinomas of 60 patients for chromosomal imbalances. The most common alteration was DNA overrepresentation on chromosome 1q, with a peak incidence at 1q22-q23 in 73% of the primary tumours, followed by DNA overrepresentation on chromosomes 8q and 20q, and deletions on chromosomes 3p, 4q, 6q, 9p, 9q, and 13q, in at least 60%. The generation of a difference histogram of metastasizing versus non-metastasizing tumours and a case-by-case histogram for the comparison of 23 paired samples of primary tumours and corresponding metastases suggested that deletions on chromosomes 3p12-p14, 3p22-p24, 4p13-15.1, 4q21-qter, 6q21-qter, 8p, 10q, 14q21, 17p12-p13, 20p12, and 21q, and overrepresentations on chromosomes 1q21-q25, 7q11.2, 9q34, 11q12-q13, 14q11-q13, and 17q25 are associated with the metastatic phenotype. In contrast, losses on chromosome 19 and gains on 3p, 4q, 5p, and 6q were preferentially found in non-metastasizng tumours. The analysis of the paired samples revealed considerable chromosomal instability, but indicated a clonal relationship in each case. The primary tumours often showed additional deletions, suggesting that loss of function mutations are critical in the initial phase of tumour dissemination, whereas the metastases preferentially acquired DNA gains, probably modulating the metastatic phenotype. The primary data from this study (ratio profiles, clinicopathological parameters, histograms) are also available at http://amba.charite.de/cgh. Copyright (C) 2001 John Wiley Sons, Ltd.
引用
收藏
页码:8 / 16
页数:9
相关论文
共 38 条
[1]
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[2]
Balsara BR, 1997, CANCER RES, V57, P2116
[3]
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer [J].
Betticher, DC ;
Heighway, J ;
Hasleton, PS ;
Altermatt, HJ ;
Ryder, WDJ ;
Cerny, T ;
Thatcher, N .
BRITISH JOURNAL OF CANCER, 1996, 73 (03) :294-300
[4]
Genetic imbalances with impact on survival in head and neck cancer patients [J].
Bockmühl, U ;
Schlüns, K ;
Küchler, I ;
Petersen, S ;
Petersen, I .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (02) :369-375
[5]
Bockmuhl U, 1997, CANCER RES, V57, P5213
[6]
Genome screening by comparative genomic hybridization [J].
Forozan, F ;
Karhu, R ;
Kononen, J ;
Kallioniemi, A ;
Kallioniemi, OP .
TRENDS IN GENETICS, 1997, 13 (10) :405-409
[7]
Gebhart E, 2000, INT J ONCOL, V16, P383
[8]
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas [J].
Ghadimi, BM ;
Schröck, E ;
Walker, RL ;
Wangsa, D ;
Jauho, A ;
Meltzer, PS ;
Ried, T .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (02) :525-536
[9]
GINSBERG J, 1997, CANC PRINCIPLES PRAC, V1, P858
[10]
Gronwald J, 1997, CANCER RES, V57, P481